268 related articles for article (PubMed ID: 37815847)
21. Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.
Taieb J; Lonardi S; Desai J; Folprecht G; Gallois C; Marques EP; Khan S; Castagné C; Wasan H
Clin Colorectal Cancer; 2023 Mar; 22(1):59-66. PubMed ID: 36653241
[TBL] [Abstract][Full Text] [Related]
22. Encorafenib in Combination With Cetuximab After Systemic Therapy in Patients With BRAF
Stintzing S; Seufferlein T; Rosé C; Reichenbach F; Lüftner D
Clin Colorectal Cancer; 2022 Sep; 21(3):244-251. PubMed ID: 35654691
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of Lynch syndrome, BRAF
Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
[TBL] [Abstract][Full Text] [Related]
24. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
[TBL] [Abstract][Full Text] [Related]
25. KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
André T; Pietrantonio F; Avallone A; Gumus M; Wyrwicz L; Kim JG; Yalcin S; Kwiatkowski M; Lonardi S; Zolnierek J; Odeleye-Ajakaye A; Leconte P; Fogelman D; Kim TW
Future Oncol; 2023 Dec; 19(37):2445-2452. PubMed ID: 37701986
[TBL] [Abstract][Full Text] [Related]
26. [BRAF-V600E testing in metastatic colorectal cancer and new, chemotherapy-free therapy options. German version].
Hummel M; Hegewisch-Becker S; Neumann J; Vogel A
Pathologe; 2021 Nov; 42(6):578-590. PubMed ID: 33956173
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
28. The Evolving Treatment Landscape in
Tabernero J; Ros J; Élez E
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
[TBL] [Abstract][Full Text] [Related]
29. Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.
Hafliger E; Boccaccino A; Lapeyre-Prost A; Perret A; Gallois C; Antista M; Pilla L; Lecomte T; Scartozzi M; Soularue E; Salvatore L; Bourgeois V; Salati M; Tougeron D; Evesque L; Vaillant JN; El-Khoury R; Lonardi S; Cremolini C; Taieb J
Eur J Cancer; 2022 Jun; 168():34-40. PubMed ID: 35436675
[TBL] [Abstract][Full Text] [Related]
30. Encorafenib, Binimetinib, and Cetuximab in
Kopetz S; Grothey A; Yaeger R; Van Cutsem E; Desai J; Yoshino T; Wasan H; Ciardiello F; Loupakis F; Hong YS; Steeghs N; Guren TK; Arkenau HT; Garcia-Alfonso P; Pfeiffer P; Orlov S; Lonardi S; Elez E; Kim TW; Schellens JHM; Guo C; Krishnan A; Dekervel J; Morris V; Calvo Ferrandiz A; Tarpgaard LS; Braun M; Gollerkeri A; Keir C; Maharry K; Pickard M; Christy-Bittel J; Anderson L; Sandor V; Tabernero J
N Engl J Med; 2019 Oct; 381(17):1632-1643. PubMed ID: 31566309
[TBL] [Abstract][Full Text] [Related]
31. The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.
Trullas A; Delgado J; Koenig J; Fuerstenau U; Dedorath J; Hausmann S; Stock T; Enzmann H; Pignatti F
ESMO Open; 2021 Feb; 6(1):100031. PubMed ID: 33422765
[TBL] [Abstract][Full Text] [Related]
32. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
Grothey A; Fakih M; Tabernero J
Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
[TBL] [Abstract][Full Text] [Related]
33. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Metastatic Colorectal Cancer in the USA.
Li S; Hu H; Ding D; Zhu Y; Huang J
Adv Ther; 2021 Mar; 38(3):1650-1659. PubMed ID: 33569738
[TBL] [Abstract][Full Text] [Related]
35. Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.
Trouiller JB; Macabeo B; Poll A; Howard D; Buckland A; Sivignon M; Clay E; Malka D; Samalin E; Toumi M; Laramée P
BMJ Open; 2022 Nov; 12(11):e063700. PubMed ID: 36410812
[TBL] [Abstract][Full Text] [Related]
36. BRAF testing in metastatic colorectal carcinoma and novel, chemotherapy-free therapeutic options.
Hummel M; Hegewisch-Becker S; Neumann JHL; Vogel A
Pathologe; 2021 Nov; 42(Suppl 1):98-109. PubMed ID: 34259881
[TBL] [Abstract][Full Text] [Related]
37. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
38. Treatment of patients with BRAF
Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C
ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
40. Nursing care and management of adverse events for patients with BRAF
Fowler M; Tobback H; Karuri A; Fernández-Ortega P
Support Care Cancer; 2023 Mar; 31(4):204. PubMed ID: 36881161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]